Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Post-Market Trading 05-09 17:18:10 EDT

133.13

-0.80

-0.60%

盘后133.13

+0.000.00%

16:01 EDT

High134.80	Low132.80	Vol201.49K
Open134.80	D1 Closing133.93	Amplitude1.49%
Mkt Cap7.61B	Tradable Cap7.55B	Total Shares57.13M
T/O26.95M	T/O Rate0.36%	Tradable Shares56.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":133.13,"timestamp":1715284800000,"preClose":133.93,"halted":0,"volume":201487,"hourTrading":{"tag":"盘后","latestPrice":133.13,"preClose":133.13,"latestTime":"16:01 EDT","volume":3238,"amount":431074.94,"timestamp":1715284876952},"delay":0,"floatShares":56674679,"shares":57131365,"eps":-9.57998,"marketStatus":"Post-Market Trading","change":-0.8,"latestTime":"05-09 17:18:10 EDT","open":134.8,"high":134.8,"low":132.8,"amount":26948877.9088,"amplitude":0.014933,"askPrice":135.77,"askSize":12,"bidPrice":133.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.57998,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1715299200000},"marketStatusCode":4,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":133.93,"postHourTrading":{"tag":"盘后","latestPrice":133.13,"preClose":133.13,"latestTime":"16:01 EDT","volume":3238,"amount":431074.94,"timestamp":1715284876952},"volumeRatio":0.46528},"requestUrl":"/m/hq/s/ASND","defaultTab":"news","newsList":[{"id":"2433930427","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Owens & Minor (OMI) and Illumina (ILMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433930427","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433930427?lang=en_us&edition=fundamental","pubTime":"2024-05-08 12:20","pubTimestamp":1715142010,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ascendis Pharma (ASND – Research Report), Owens & Minor (OMI – Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ascendis-pharma-asnd-owens-minor-omi-and-illumina-ilmn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ascendis-pharma-asnd-owens-minor-omi-and-illumina-ilmn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432437911","title":"Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2432437911","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432437911?lang=en_us&edition=fundamental","pubTime":"2024-05-04 21:07","pubTimestamp":1714828075,"startTime":"0","endTime":"0","summary":"NasdaqGS:ASND Earnings and Revenue Growth May 4th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 18%. Earnings per share  missed analyst estimates by 61%.Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's share price is broadly unchanged from a week ago.Before we wrap up, we've discovered 2 warning signs for Ascendis Pharma (1 shouldn't be ignored!","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascendis-pharma-first-quarter-2024-130755803.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432250968","title":"Ascendis Pharma A/S Boasts Strong Q1 Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2432250968","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432250968?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:58","pubTimestamp":1714687138,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S has reported a substantial first quarter growth in 2024, with SKYTROFA reven...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-boasts-strong-q1-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-boasts-strong-q1-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432968233","title":"Ascendis Pharma Posts Q1 Revenue Growth Amid Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2432968233","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432968233?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:57","pubTimestamp":1714687046,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S, a biopharmaceutical company, reported increased revenue of EUR 95,894,000 f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-posts-q1-revenue-growth-amid-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-posts-q1-revenue-growth-amid-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432951791","title":"Ascendis Pharma Outlines AGM Agenda and Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2432951791","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432951791?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:58","pubTimestamp":1714683527,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S has announced its Annual General Meeting (AGM) scheduled for May 30th, 2024,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-outlines-agm-agenda-and-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-outlines-agm-agenda-and-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432959255","title":"Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2432959255","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432959255?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:46","pubTimestamp":1714682763,"startTime":"0","endTime":"0","summary":"Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38599562/ascendis-pharma-q1-sales-95-894m-beat-79-492m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2432593069","title":"Ascendis Pharma reports Q1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2432593069","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432593069?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:41","pubTimestamp":1714682481,"startTime":"0","endTime":"0","summary":"Ascendis Pharma press release : Q1 GAAP EPS of -2.30. Revenue of 95.9M . Cash, cash equivalents, and marketable securities totaling 320 million compared to 399 million as of December 31, 2023. Full year 2024 SKYTROFA revenue expected to be 320 million to 340 million .  Expect total operating expenses  of approximately 600 million for 2024. Expect to be operating cash flow breakeven on a quarterly basis by the end of 2024.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099201-ascendis-pharma-reports-q1-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2432953131","title":"Press Release: Ascendis Pharma Reports First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2432953131","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432953131?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:01","pubTimestamp":1714680060,"startTime":"0","endTime":"0","summary":"-- Rollout of YORVIPATH initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and 100 patients receiving commercial product as of March 31. -- TransCon CNP  pivotal ApproaCH Trial on track for topline results in Q4 2024. -- SKYTROFA Q1 revenue more than doubled year-over-year to EUR65 million; Q1 operating expenses fell by 20% year-over-year to EUR137 million. -- Ascendis remains on track for achieving full-year 2024 SKYTROFA revenue of EUR320 to EUR340 million and full year 2024 operating expenses of EUR600 million. COPENHAGEN, Denmark, May 02, 2024  -- Ascendis Pharma A/S  today announced financial results for the first quarter ended March 31, 2024, and provided a business update.patients receiving commercial product as of March 31. First","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432561756","title":"Ascendis Pharma Q1 2024 Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432561756","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432561756?lang=en_us&edition=fundamental","pubTime":"2024-05-02 05:20","pubTimestamp":1714598452,"startTime":"0","endTime":"0","summary":"Ascendis Pharma  is scheduled to announce Q1 earnings results on Thursday, May 2nd, after market close.The consensus EPS Estimate is -$1.50 and the consensus Revenue Estimate is $84.93M .Over the last 3 months, EPS estimates have seen 3 upward revisions and 1 downward. Revenue estimates have seen 5 upward revisions  and 0 downward.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097520-ascendis-pharma-q1-2024-earnings-preview","is_publish_highlight":false,"gpt_icon":0},{"id":"2429451317","title":"Ascendis Pharma Gains UK Authorization for YORVIPATH","url":"https://stock-news.laohu8.com/highlight/detail?id=2429451317","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2429451317?lang=en_us&edition=fundamental","pubTime":"2024-04-24 21:57","pubTimestamp":1713967077,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S has achieved a significant milestone by obtaining marketing authorization fr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-gains-uk-authorization-for-yorvipath?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-gains-uk-authorization-for-yorvipath?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2429454024","title":"Why Earnings Season Could Be Great for Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429454024","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429454024?lang=en_us&edition=fundamental","pubTime":"2024-04-24 20:34","pubTimestamp":1713962040,"startTime":"0","endTime":"0","summary":"Investors are always looking for stocks that are poised to beat at earnings season and Ascendis Pharma A/S ASND may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Ascendis Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ASND in this report.In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $1.36 per share for ASND, narrower than the broader Zacks Consensus Estimate of a loss of $1.57 per share. This suggests that analysts have very recently bumped up their estimates for ASND, giving the stock a Zacks Earnings ESP of +13.61% heading into earnings season.Ascendis Pharma A/S price-eps-surprise | Ascend","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-earnings-season-could-great-123400861.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426780919","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426780919","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426780919?lang=en_us&edition=fundamental","pubTime":"2024-04-12 21:41","pubTimestamp":1712929300,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amphastar Pharmaceuticals (AMPH – Research Report), Ascendis Phar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amphastar-pharmaceuticals-amph-ascendis-pharma-asnd-and-amn-healthcare-services-amn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amphastar-pharmaceuticals-amph-ascendis-pharma-asnd-and-amn-healthcare-services-amn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426233923","title":"Ascendis Pharma A/S Outlines Financial Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2426233923","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426233923?lang=en_us&edition=fundamental","pubTime":"2024-04-11 16:37","pubTimestamp":1712824644,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S has updated its Articles of Association, detailing the company’s fully paid ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-outlines-financial-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-outlines-financial-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422792428","title":"Ascendis Pharma Updates Share Capital Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2422792428","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422792428?lang=en_us&edition=fundamental","pubTime":"2024-03-28 05:27","pubTimestamp":1711574876,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S, a company focused on developing medical treatments for diseases, has made s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-updates-share-capital-structure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-updates-share-capital-structure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422764399","title":"GOP committee opposes cannabis banking bill; calls marijuana 'gateway drug'","url":"https://stock-news.laohu8.com/highlight/detail?id=2422764399","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422764399?lang=en_us&edition=fundamental","pubTime":"2024-03-26 23:34","pubTimestamp":1711467250,"startTime":"0","endTime":"0","summary":"Trulieve's Triumph: Navigating Growth And 280E Tax In The Green Rush Americans overwhelmingly support cannabis banking reform - poll Cannabis stocks spike as VP Kamala Harris urges immediate rescheduling","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083800-gop-committee-opposes-cannabis-banking-bill-calls-marijuana-gateway-drug","is_publish_highlight":false,"gpt_icon":0},{"id":"2422279875","title":"Americans overwhelmingly support cannabis banking reform - poll","url":"https://stock-news.laohu8.com/highlight/detail?id=2422279875","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422279875?lang=en_us&edition=fundamental","pubTime":"2024-03-26 03:06","pubTimestamp":1711393566,"startTime":"0","endTime":"0","summary":"A recent poll from the American Bankers Association found that 63% of Americans favor allowing cannabis businesses access to the U.S. financial system. This would include access to banking services such as checking accounts and business loans in states where marijuana has been legalized.  The poll found that 36% of respondents strongly support Congress passing cannabis banking legislation with 27% saying they somewhat support it. \"Americans have made it clear that Congress should resolve the ongoing conflict between state and federal law on cannabis banking issues by passing legislation that will enhance public safety, tax collection and transparency,\" said ABA President and CEO Rob Nichols in a news release. Multi-state operators: Ascend Wellness , Curaleaf Holdings , Cresco Labs , Green Thumb Industries , Trulieve Cannabis , Ayr Wellness , Verano Holdings , and Jushi Holdings . Canadian cannabis companies: Tilray Brands , Canopy Growth , and Aurora Cannabis .   More on marijuana comp","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213258764/image_1213258764.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213258764/image_1213258764.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083376-americans-overwhelmingly-support-cannabis-banking-reform","is_publish_highlight":false,"gpt_icon":0},{"id":"2421325846","title":"Are Medical Stocks Lagging  AdaptHealth (AHCO) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2421325846","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2421325846?lang=en_us&edition=fundamental","pubTime":"2024-03-22 21:40","pubTimestamp":1711114811,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AdaptHealth Corp.  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AdaptHealth Corp. is one of 1063 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AdaptH","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-adapthealth-ahco-134011669.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":-0.0502},{"period":"1month","weight":-0.1004},{"period":"3month","weight":-0.0382},{"period":"6month","weight":0.4835},{"period":"1year","weight":0.3779},{"period":"ytd","weight":0.0634}],"compareEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":-0.0029},{"period":"3month","weight":0.0379},{"period":"6month","weight":0.1738},{"period":"1year","weight":0.2586},{"period":"ytd","weight":0.0881}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.037189},{"month":2,"riseRate":0.5,"avgChangeRate":0.037735},{"month":3,"riseRate":0.5,"avgChangeRate":0.039038},{"month":4,"riseRate":0.3,"avgChangeRate":-0.046884},{"month":5,"riseRate":0.4,"avgChangeRate":-0.000235},{"month":6,"riseRate":0.555556,"avgChangeRate":0.01785},{"month":7,"riseRate":0.666667,"avgChangeRate":0.002177},{"month":8,"riseRate":0.666667,"avgChangeRate":0.086396},{"month":9,"riseRate":0.555556,"avgChangeRate":0.037325},{"month":10,"riseRate":0.444444,"avgChangeRate":0.006164},{"month":11,"riseRate":0.777778,"avgChangeRate":0.039978},{"month":12,"riseRate":0.444444,"avgChangeRate":0.049536}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction